` CHM (Chimeric Therapeutics Ltd) vs S&P/ASX 300 Comparison - Alpha Spread

CHM
vs
S
S&P/ASX 300

Over the past 12 months, CHM has underperformed S&P/ASX 300, delivering a return of -33% compared to the S&P/ASX 300's +6% growth.

Stocks Performance
CHM vs S&P/ASX 300

Loading
CHM
S&P/ASX 300
Add Stock
www.alphaspread.com
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Performance Gap
CHM vs S&P/ASX 300

Loading
CHM
S&P/ASX 300
Difference
www.alphaspread.com

Performance By Year
CHM vs S&P/ASX 300

Loading
CHM
S&P/ASX 300
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Competitors Performance
Chimeric Therapeutics Ltd vs Peers

S&P/ASX 300
CHM
ABBV
AMGN
GILD
VRTX
Add Stock
No Stocks Selected

Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.

Select Stock to Compare

Chimeric Therapeutics Ltd
Glance View

Market Cap
14.6m AUD
Industry
Biotechnology

Chimeric Therapeutics Ltd. develops Chlorotixin CAR-T technology based cell therapies for the curation of solid tumors. The company is headquartered in Melbourne, Victoria. The company went IPO on 2021-01-18. The firm's technology known as CLTX-CAR T, uses chlorotoxin, a peptide discovered in scorpion venom, as the tumor-targeting component of the CAR to reprogram T cells. The CAR T cell is an immune T cell taken from a patient’s blood which is sent to a lab where it is re-programmed to become a charged guided missile, to seek out a specific target on the surface of a cancer cell.

CHM Intrinsic Value
0.007 AUD
Undervaluation 43%
Intrinsic Value
Price
Back to Top